Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Commentary|Articles|June 5, 2026
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
Author(s)Riley Kandel
Fact checked by: Chris Ryan
Experts delineate the biggest presentations they are looking forward to being presented at the 2026 EHA Congress.
Advertisement
Advertisement
The upcoming
Related to this article
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Advertisement
Advertisement